Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients-Reference-Cited by-同舟云学术

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

Published:2018-11-16 Issue:2 Volume:98 Page:321-330
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

García-Gutiérrez Valentín, ,Milojkovic Dragana,Hernandez-Boluda Juan Carlos,Claudiani Simone,Martin Mateos María Luisa,Casado-Montero Luis Felipe,González Gloria,Jimenez-Velasco Antonio,Boque Concepcion,Martinez-Trillos Alejandra,Vázquez Isabel Mata,Payer Ángel Ramírez,Senín Alicia,Amustio Díez Elena,García Abelardo Bárez,Carrascosa Guiomar Bautista,Ortí Guillermo,Ruiz Beatriz Cuevas,Fernández Maria Ángeles,del Carmen García Garay María,Giraldo Pilar,Guinea Jose María,De Las Heras Rodríguez Natalia,Hernán Nuria,Pérez Ana Iglesias,Piris-Villaespesa Miguel,Lorenzo Jose Luis López,Martí-Tutusaus Josep Maria Martí,Vallansot Rolando Omar,Ortega Rivas Fernando,Puerta Jose Manuel,Ramirez Maria Jose,Romero Esperanza,Romo Andres,Rosell Ana,Saavedra Silvanna Saavedra,Sebrango Ana,Tallon José,Valencia Sandra,Portero Angeles,Steegmann Juan Luis

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-018-3507-2/fulltext.html

Reference23 articles.

1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884

2. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 34:2333–2340

3. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044–1054

4. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27:107–112

5. Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brummendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G (2014) Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 123:2317–2324

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia;Frontiers in Oncology;2024-08-26

2. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

3. Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia;Annals of Hematology;2024-07-18

4. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML;Annals of Hematology;2024-04-18

5. Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia;Journal of Oncology Pharmacy Practice;2023-12-17